Directors of five NIH institutes have been placed on administrative leave or offered new assignments as part of sweeping HHS ...

For a variety of reasons, Globe Food contributor Kara Baskin took the leap and started Zepbound. But first she worried: "What ...

Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co.'s Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed ...

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

While tariffs have triggered market volatility, certain pharmaceutical stocks still present strong investment opportunities.

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Breen pointed out the difficulty in distinguishing the anti-cancer effects of weight loss alone from the additional anti-cancer ... Moreover, Eli Lilly announced a $27 billion investment in U.S.

Eli Lilly & Co. (NYSE: LLY) launched its own GLP-1/GIP dual agonist treatment for obesity, Zepbound, in December 2023. Zepbound is the most effective FDA-approved GLP-1 drug for weight loss ... a ...